MedTrace Logo

A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients

NCT03569553 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-02-06

No results posted yet for this study

Summary

This study will evaluate safety and clinical benefit of AIGIV used for treatment of patients with inhalational anthrax. This study will be implemented only in the event of a major anthrax exposure event. The study is designed to collect information on safety, clinical benefit (such as extent of anthrax illness and survival) and serum concentrations of AIGIV (for AIGIV pharmacokinetics) and anthrax toxins from inhalational anthrax patients treated with AIGIV.

Conditions

  • Inhalational Anthrax

Interventions

DRUG

AIGIV

Anthrax Immune Globulin Intravenous (Human)

Sponsors & Collaborators

Principal Investigators

  • Brandon Essink, MD

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-05-30
Primary Completion
2027-07-31
Completion
2027-07-31
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03569553 on ClinicalTrials.gov